2018
DOI: 10.1016/j.endien.2018.11.003
|View full text |Cite
|
Sign up to set email alerts
|

Clinical value of Flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(8 citation statements)
references
References 26 publications
2
6
0
Order By: Relevance
“…The results of this study confirm what has already been shown in numerous trials [7][8][9][10][11][12][13][14][15]. The simplicity and ease of use of the FGM system which was confirmed by frequent scans on daily basis exactly according to the recommendations, even increasing slightly by the end of one year indicating high level of adherence and compliance resulting in the improvement of HbA1c.…”
Section: Discussionsupporting
confidence: 89%
See 2 more Smart Citations
“…The results of this study confirm what has already been shown in numerous trials [7][8][9][10][11][12][13][14][15]. The simplicity and ease of use of the FGM system which was confirmed by frequent scans on daily basis exactly according to the recommendations, even increasing slightly by the end of one year indicating high level of adherence and compliance resulting in the improvement of HbA1c.…”
Section: Discussionsupporting
confidence: 89%
“…There was a decrease in HbA1c in the entire cohort of patients occurring in the first 3 months with no further changes to the end of one year confirming that majority of improvement in glucoregulation is taking place at the very beginning of FGM implementation in glycemic management, supporting evidence of presently published observational trials [7][8][9][10][11][12][13][14][15]. As the FGM metrics were not available at baseline, data from T3 to 12 were analyzed showing a significant increase in the time spent in range (TIR) and significant decrease in time spent in hyperglycemia (TAR).…”
Section: Discussionsupporting
confidence: 74%
See 1 more Smart Citation
“…35 Subsequent real-world observational studies demonstrated improvements in glycemic control and quality of life, less disease burden and a decrease in the number of hospital admissions and days of work absenteeism. 1,611…”
Section: Introductionmentioning
confidence: 99%
“…[3][4][5] Subsequent real-world observational studies demonstrated improvements in glycemic control and quality of life, less disease burden and a decrease in the number of hospital admissions and days of work absenteeism. 1,[6][7][8][9][10][11] While the isCGM has shown its potential to reduce costs of T1D-related morbidities, the device incurs a certain cost. Therefore, cost-effectiveness assessment should be conducted.…”
Section: Introductionmentioning
confidence: 99%